Pancreatic Cancer Research

ResearcherSecond Hospital of Tianjin Medical UniversityActive in the last 2 years

Jinjin Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3676-1437; OpenAlex author ID A5040197406. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers

Papers 9

  1. Chemotherapy-associated mutational process signature and genomic alterations associated with outcome in metastatic pancreatic cancer. Last author DOI 10.1007/s12094-025-03975-1↗
  2. Hypoxia- and lactate metabolism-associated prognostic and therapeutic signature in pancreatic cancer. Last author DOI 10.1007/s12672-025-02873-w↗
  3. USP10 promotes the progression and attenuates gemcitabine chemotherapy sensitivity via stabilizing PLK1 in PDAC. Last author DOI 10.1038/s41419-025-07757-z↗
  4. Construction of a pancreatic cancer prediction model for oxidative stress-related lncRNA. Last author DOI 10.1007/s10142-023-01048-6↗
  5. Aspirin use and pancreatic cancer risk: A systematic review of observational studies. Co-author DOI 10.1097/md.0000000000018033↗
  6. Downregulation of miR-21 inhibits the malignant phenotype of pancreatic cancer cells by targeting VHL. Co-author DOI 10.2147/ott.s211535↗
  7. FOXO3a expression and its diagnostic value in pancreatic ductal adenocarcinoma. Last author PMID 31949625↗
  8. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis. Last author DOI 10.18632/oncotarget.18091↗
  9. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized cont… First author DOI 10.1179/1973947815y.0000000013↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhijia Jiang · 6 shared papers, 2015–2025 · strength 0.91
  2. Hao Yao · 2 shared papers, 2023–2025 · strength 0.54
  3. Chenhui Zhang · 2 shared papers, 2025 · strength 0.54
  4. Yaqing Wei · 2 shared papers, 2025 · strength 0.45
  5. Kaiqiang Wang · 3 shared papers, 2017–2025 · strength 0.41
  6. Yanxun Li · 3 shared papers, 2015–2019 · strength 0.30
  7. Geng Liu · 3 shared papers, 2015–2019 · strength 0.28
  8. Hao Huang · 1 shared paper, 2023 · strength 0.24
  9. Ming Chen · 1 shared paper, 2023 · strength 0.24
  10. Xuezhi Du · 1 shared paper, 2025 · strength 0.24
  11. Geng Liu · 2 shared papers, 2018–2019 · strength 0.21
  12. Dong Su Yu · 1 shared paper, 2018 · strength 0.10
  13. Shuang Feng · 1 shared paper, 2018 · strength 0.10
  14. Jun Li · 1 shared paper, 2018 · strength 0.10
  15. Xing Chen · 1 shared paper, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.